Your browser is no longer supported. Please, upgrade your browser.
Settings
ALXO [NASD]
ALX Oncology Holdings Inc.
Index- P/E- EPS (ttm)-1.90 Insider Own1.90% Shs Outstand18.48M Perf Week3.70%
Market Cap2.53B Forward P/E- EPS next Y-2.62 Insider Trans-3.67% Shs Float17.09M Perf Month-9.98%
Income-50.90M PEG- EPS next Q-0.41 Inst Own80.90% Short Float13.65% Perf Quarter-18.90%
Sales1.20M P/S2105.35 EPS this Y-311.10% Inst Trans0.28% Short Ratio9.06 Perf Half Y48.39%
Book/sh23.25 P/B2.79 EPS next Y-29.10% ROA-22.40% Target Price98.43 Perf Year-
Cash/sh11.17 P/C5.82 EPS next 5Y- ROE-39.10% 52W Range28.01 - 117.45 Perf YTD-24.62%
Dividend- P/FCF- EPS past 5Y- ROI-10.40% 52W High-47.46% Beta-
Dividend %- Quick Ratio70.30 Sales past 5Y- Gross Margin9.10% 52W Low120.31% ATR4.69
Employees23 Current Ratio70.30 Sales Q/Q-100.00% Oper. Margin- RSI (14)45.13 Volatility5.61% 7.71%
OptionableYes Debt/Eq0.00 EPS Q/Q-299.00% Profit Margin- Rel Volume0.71 Prev Close64.98
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume257.60K Price61.71
Recom1.90 SMA20-0.75% SMA50-10.32% SMA2000.46% Volume184,133 Change-5.03%
May-05-21Resumed Credit Suisse Outperform $98
Apr-26-21Resumed Credit Suisse Outperform $98
Apr-06-21Initiated UBS Buy
Feb-10-21Initiated H.C. Wainwright Buy $100
Aug-11-20Initiated Piper Sandler Overweight $55
Aug-11-20Initiated Jefferies Buy $50
Aug-11-20Initiated Credit Suisse Outperform $53
Aug-11-20Initiated Cantor Fitzgerald Overweight $64
May-10-21 07:00AM  
Apr-21-21 04:05PM  
Apr-16-21 01:41AM  
Apr-05-21 07:00AM  
Mar-18-21 04:05PM  
Mar-15-21 07:00AM  
Mar-05-21 08:15AM  
Mar-04-21 04:05PM  
Mar-03-21 08:34AM  
Mar-02-21 07:00AM  
Feb-10-21 10:05AM  
Jan-16-21 01:12AM  
Jan-11-21 07:00AM  
Jan-05-21 07:00AM  
Dec-17-20 07:00AM  
Dec-14-20 04:05PM  
Dec-11-20 10:55PM  
Dec-09-20 10:26PM  
Dec-07-20 04:08PM  
10:00AM  
07:00AM  
Nov-24-20 07:00AM  
Nov-12-20 04:05PM  
Nov-09-20 08:10AM  
Nov-05-20 07:00AM  
Nov-02-20 07:00AM  
Oct-28-20 07:00AM  
Oct-14-20 04:25PM  
Oct-06-20 07:00AM  
Sep-22-20 07:00AM  
Sep-17-20 07:00AM  
Sep-08-20 07:00AM  
Aug-27-20 04:05PM  
Jul-21-20 04:05PM  
Jul-17-20 04:17PM  
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell; human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma; and HER2-expressing breast cancer. The company's pre-clinical products include SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with advanced HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was incorporated in 2015 and is based in Burlingame, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pons JaumePresident & CEOApr 19Sale57.6316,700962,433544,646Apr 21 04:14 PM
Randolph SophiaChief Medical OfficerApr 12Sale59.437,387438,978193,750Apr 13 04:05 PM
Pons JaumePresident & CEOMar 25Option Exercise0.9910,0009,900561,346Mar 26 09:39 PM
Pons JaumePresident and CEOMar 22Option Exercise1.9116,70031,897568,046Mar 24 04:05 PM
Pons JaumePresident and CEOMar 22Sale68.4916,7001,143,860551,346Mar 24 04:05 PM
Randolph SophiaChief Medical OfficerMar 10Sale74.347,387549,173201,137Mar 12 09:39 PM
GARCIA PETER SChief Financial OfficerJan 28Option Exercise4.086,12825,0029,128Jan 29 04:15 PM
Pons JaumePresident & CEOJan 26Option Exercise0.9910,0009,900551,346Jan 28 06:01 AM
Graham G. WalmsleyDirectorDec 14Buy76.0020,0001,520,000995,000Dec 15 07:07 PM